Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All convalescent plasma..
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchConvalescent PlasmaConv. Plasma (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   All Outcomes    Recent:   
0 0.5 1 1.5 2+ Mortality, day 28 12% Improvement Relative Risk Mortality, day 14 1% WHO scale, day 28 8% WHO scale, day 14 6% primary PASC, all categories com.. -2% PASC, general 5% PASC, gastrointestinal -15% PASC, neurological 18% PASC, respiratory -18% Conv. Plasma  CONTAIN COVID-19  LATE TREATMENT  DB RCT Is late treatment with convalescent plasma beneficial for COVID-19? Double-blind RCT 941 patients in the USA (April 2020 - March 2021) Lower mortality with convalescent plasma (not stat. sig., p=0.45) c19early.org Ortigoza et al., JAMA Internal Medicine, Dec 2021 Favors conv. plasma Favors control

Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients

Ortigoza et al., JAMA Internal Medicine, doi:10.1001/jamainternmed.2021.6850, CONTAIN COVID-19, NCT04364737
Dec 2021  
  Post
  Facebook
Share
  Source   PDF   All   Meta
RCT 941 hospitalized patients in the USA, showing no significant difference with convalescent plasma treatment. PASC results are from Yoon et al.
risk of death, 11.8% lower, RR 0.88, p = 0.45, treatment 59 of 462 (12.8%), control 71 of 462 (15.4%), NNT 39, odds ratio converted to relative risk, day 28.
risk of death, 1.3% lower, RR 0.99, p = 0.95, treatment 35 of 463 (7.6%), control 39 of 463 (8.4%), NNT 116, odds ratio converted to relative risk, day 14.
WHO scale, 7.6% lower, OR 0.92, p = 0.50, treatment 468, control 473, day 28, RR approximated with OR.
WHO scale, 6.4% lower, OR 0.94, p = 0.58, treatment 468, control 473, day 14, primary outcome, RR approximated with OR.
risk of PASC, 2.4% higher, RR 1.02, p = 0.88, treatment 141, control 140, all categories combined.
risk of PASC, 5.0% lower, OR 0.95, p = 0.87, treatment 141, control 140, general, RR approximated with OR.
risk of PASC, 15.0% higher, OR 1.15, p = 0.70, treatment 141, control 140, gastrointestinal, RR approximated with OR.
risk of PASC, 18.0% lower, OR 0.82, p = 0.54, treatment 141, control 140, neurological, RR approximated with OR.
risk of PASC, 18.0% higher, OR 1.18, p = 0.53, treatment 141, control 140, respiratory, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ortigoza et al., 13 Dec 2021, Double Blind Randomized Controlled Trial, placebo-controlled, USA, peer-reviewed, median age 63.0, 268 authors, study period 17 April, 2020 - 15 March, 2021, average treatment delay 7.0 days, trial NCT04364737 (history) (CONTAIN COVID-19). Contact: l.pirofski@einsteinmed.org.
This PaperConv. PlasmaAll
Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients
MD Mila B Ortigoza, PhD Hyunah Yoon, MD Keith S Goldfeld, ScD Andrea B Troxel, MD, MS Johanna P Daily, MA Yinxiang Wu, MS Yi Li, MS Danni Wu, MA Gia F Cobb, MD Gillian Baptiste, Mary O’keeffe, MD Marilou O Corpuz, MD Luis Ostrosky-Zeichner, MD Amee Amin, MD Ioannis M Zacharioudakis, MD Dushyantha T Jayaweera, MD Yanyun Wu, MD Julie V Philley, MD Megan S Devine, MD Mahalia S Desruisseaux, MD Alessandro D Santin, MD Shweta Anjan, MBBS Reeba Mathew, MD Bela Patel, MD Masayuki Nigo, MD Rabi Upadhyay, MD Tania Kupferman, MD Andrew N Dentino, MD Rahul Nanchal, MS Christian A Merlo, MD, MPH David N Hager, PhD Kartik Chandran, PhD Jonathan R Lai, PhD Johanna Rivera, PhD Chowdhury R Bikash, PhD Gorka Lasso, PhD Timothy P Hilbert, MD Monika Paroder, MD, PhD Andrea A Asencio, BA Mengling Liu, PhD; Eva Petkova, PhD; Alexander Bragat, MBA Reza Shaker, MD David D Mcpherson, MD Ralph L Sacco, MD, MS Marla J Keller, MD Corita R Grudzen, MD Judith S Hochman, MD Liise-Anne Pirofski, Fatema Z Rahman, Adeyinka O Ajayi, Sara L Rodriguez, Ana G Ledesma, Deborah Keeling, Norka Rappoport, Sam F Ebel, Jayne Kim, Michelle Chang, Kevin Chan, Payal Patel, Anne Martocci, Shivang Dave, Yousef Darwish, Monica Taveras, Victoria Shoyelu, Patrick Xin, Eduardo Iturrate, Lee C Moldolsky, Brian J Raimondo, Sarah Mendez, Patricia Hughes, Stephanie Sterling, Aaron S Lord, Shadi Yaghi, Karen Veloso, Masooma Sheikh, Erica Visconti-Ferrara, Andrew Fleming, Heekoung Youn, Baby Jane Fran, Rosario Medina, Renee Mckell, Saila Khan, Tanya Hamilton, Carlos J Sanchez, Nandini H Patel, Levi Cleare, Olivia Vergnolle, Antonio Nakouzi, Gregory Quevedo, Robert H Bortz, Ariel S Wirchnianski, Catalina Florez, Rachelle Babb, Jennifer Ayala, K Zoe Tsagaris, Andria James, Isaiah Eke, Aisha Obeidallah, Oana A Sandu, Sophie Sohval, Leana Serrano-Rahman, Joan Uehlinger, Rachel Bartash, Aya Al-Abduladheem, Inessa Gendlina, Carol Sheridan, Anna Bortnick, Jeremy Eichler, Rachel Kaufman, Sarah Yukelis, Michael Pennock, Michelle Goggin, Christine Shen, Jayabhargav Annam, Ahmed Khokhar, Daniel Barboto, Brianna J Lally, Audrey Lee, Max Lee, Xiuyi A Yang, Stephanie Allen, Avinash Malaviya, Omar Moussa, Rosa Park, Reise Sample, Andrea Bae, Galit Benoni, Lindsie L Boerger, Lisa D Baker, Martha A Luther, Lirim S Ameti, Neima Briggs, Marjorie R Golden, Michael Gormally, Gloria S Huang, Raymond M Johnson, Alyssa R Morrison, Michele Montagna-Hill, Brooke N Rivera, Grace M Cortezzo, Kay B Debski, Nicoletti, Kerry Debenedictis, Rivcah Davis, Christi Marshall, Miriam Andrea Duque Cuartas, Laura Beauchamps, Jovanna Bertran-Lopez, Jose Gonzales Zamora, Maria Delgado-Lelievre, Sheela Dominguez, Chin Chin Lee, Halina Kusack, Vela Karakeshishyan, Americo Hajaz, Dasmany Deniz, Giovanni Garcia, Katheryn Dae, Patricia Blenet, Deborah Jaffe, Lourdes Olson, Diane Sabogal, Olivia Blust, Veronica Del Prete Perez, Claudia Bornia, Vanessa Rodriguez-Perez, Vivian Calderon, Rajan Ramdev, Aaliyah Jolly, Ivonne Guzman, Richard Guerra, Sebastian Brito, Rhonda Hobbs, Rebecca Denham, John Dick, Maria D Hernandez, Laura E Nielsen, Sami M Anjum, Shelby C Mader, Taylor P Stutz, Mehriban Mammadova, Pamela Nichols, Tanya S Khan, Maha R Boktour, Brenda L Castaneda, Brenda D Benitez, Erik Hinojosa, Brenda C Guerra, Armando Ortiz, Renee S Hebbeler-Clark, Pamela J Mcshane, Rebekah Hibbard, Benji E Hawkins, Elizabeth R Dohanich, Carly Wadle, Kimberly L Greenlee, Jennifer Brooks, Christopher D Herrick, Amit Gode, Paul Bergl, Kurt Hu, Jayshil Patel, Shankar Srinivasan, Jeanette Graf, Char Klis, Kyersten Reimer, Erica Carpenter, Christine Naczek, Rae Petersen, Renee Dex, Jennifer Drossart, James Zelten, Charles Brummitt, Mengyao Liang, Lynda Yanny, Gary Dennison, Phyllis Runningen, Brian Brzezinski, Stephen Fiebig, Chris Naczek, Michelle Kasdorf, MD, MPH Lalitha Parameswaran, MD Anthony T Corcoran, MD Abhinav Rohatgi, MO Marta W Wronska, MD Xinyuan Wu, MD Ranjini Srinivasan, Fang-Ming Deng, PhD Thomas D Filardo, MD Jay Pendse, PhD Simone B Blaser, MD Olga Whyte, BSN, RN; Jacqueline M Gallagher, Ololade E Thomas, Danibel Ramos, Caroline L Sturm-Reganato, Charlotte C Fong, Ivy M Daus, Arianne Gisselle Payoen, Joseph T Chiofolo, Mark T Friedman, Ding Wen Wu, MD Jessica L Jacobson, MD Jeffrey G Schneider, MD Uzma N Sarwar, MD; Henry E Wang, MD Ryan M Huebinger, MD Goutham Dronavalli, MD Yu Bai
JAMA Internal Medicine, doi:10.1001/jamainternmed.2021.6850
and the CONTAIN COVID-19 Consortium for the CONTAIN COVID-19 Study Group IMPORTANCE There is clinical equipoise for COVID-19 convalescent plasma (CCP) use in patients hospitalized with COVID-19. OBJECTIVE To determine the safety and efficacy of CCP compared with placebo in hospitalized patients with COVID-19 receiving noninvasive supplemental oxygen. DESIGN, SETTING, AND PARTICIPANTS CONTAIN COVID-19, a randomized, double-blind, placebo-controlled trial of CCP in hospitalized adults with COVID-19, was conducted at 21 US hospitals from April 17, 2020, to March 15, 2021. The trial enrolled 941 participants who were hospitalized for 3 or less days or presented 7 or less days after symptom onset and required noninvasive oxygen supplementation. INTERVENTIONS A unit of approximately 250 mL of CCP or equivalent volume of placebo (normal saline). MAIN OUTCOMES AND MEASURES The primary outcome was participant scores on the 11-point World Health Organization (WHO) Ordinal Scale for Clinical Improvement on day 14 after randomization; the secondary outcome was WHO scores determined on day 28. Subgroups were analyzed with respect to age, baseline WHO score, concomitant medications, symptom duration, CCP SARS-CoV-2 titer, baseline SARS-CoV-2 serostatus, and enrollment quarter. Outcomes were analyzed using a bayesian proportional cumulative odds model. Efficacy of CCP was defined as a cumulative adjusted odds ratio (cOR) less than 1 and a clinically meaningful effect as cOR less than 0.8. RESULTS Of 941 participants randomized (473 to placebo and 468 to CCP), 556 were men (59.1%); median age was 63 years (IQR, 52-73); 373 (39.6%) were Hispanic and 132 (14.0%) were non-Hispanic Black. The cOR for the primary outcome adjusted for site, baseline risk, WHO score, age, sex, and symptom duration was 0.94 (95% credible interval [CrI], 0.75-1.18) with posterior probability (P[cOR<1] = 72%); the cOR for the secondary adjusted outcome was 0.92 (95% CrI, 0.74-1.16; P[cOR<1] = 76%). Exploratory subgroup analyses suggested heterogeneity of treatment effect: at day 28, cORs were 0.72 (95% CrI, 0.46-1.13; P[cOR<1] = 93%) for participants enrolled in April-June 2020 and 0.65 (95% CrI, 0.41 to 1.02; P[cOR<1] = 97%) for those not receiving remdesivir and not receiving corticosteroids at randomization. Median CCP SARS-CoV-2 neutralizing titer used in April to June 2020 was 1:175 (IQR, 76-379). Any adverse events (excluding transfusion reactions) were reported for 39 (8.2%) placebo recipients and 44 (9.4%) CCP recipients (P = .57). Transfusion reactions occurred in 2 (0.4) placebo recipients and 8 (1.7) CCP recipients (P = .06). CONCLUSIONS AND RELEVANCE In this trial, CCP did not meet the prespecified primary and secondary outcomes for CCP efficacy. However, high-titer CCP may have benefited participants early in the pandemic when remdesivir and corticosteroids were not in use.
References
Acquisition, Ortigoza, Yoon, Goldfeld, Troxel et al., Critical revision of the manuscript for important intellectual content
Agarwal, Mukherjee, Kumar, Chatterjee, Bhatnagar et al., Convalescent plasma in the management of moderate Covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial), BMJ, doi:10.1136/bmj.m3939
Avendaño-Solá, Ramos-Martínez, Muñez-Rubio, A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia, J Clin Invest, doi:10.1172/JCI152740
Beigel, Tomashek, Dodd, ACTT-1 Study Group Members. Remdesivir for the treatment of Covid-19 -final report, N Engl J Med, doi:10.1056/NEJMoa2007764
Bortz, Iii, Florez, Laudermilch, Single-dilution COVID-19 antibody test with qualitative and quantitative readouts, mSphere, doi:10.1128/mSphere.00224-21
Bégin, Callum, Jamula, 1 Study Group. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial, Nat Med, doi:10.1038/s41591-021-01488-2
Covid-19, Consortium, Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19, JAMA Oncol, doi:10.1001/jamaoncol.2021.1799?utm_campaign=articlePDF%26utm_medium=articlePDFlink%26utm_source=articlePDF%26utm_content=jamainternmed.2021.6850
Dieterle, Haslwanter, Bortz, Iii, A replication-competent vesicular stomatitis virus for studies of SARS-CoV-2 spike-mediated cell entry and its inhibition, Cell Host Microbe, doi:10.1016/j.chom.2020.06.020
Fibiger, Om Serumbehandling af Difteri
Focosi, Franchini, Pirofski, COVID-19 convalescent plasma and randomized clinical trials: rebuilding confidence by explaining failures and finding signals of efficacy, medRxiv, doi:10.1101/2021.09.07.21263194
Gelman, John, Carlin, Bayesian Data Analysis, doi:10.1201/b16018
Goldfeld, Wu, Tarpey, Prospective individual patient data meta-analysis: evaluating convalescent plasma for COVID-19, Stat Med, doi:10.1002/sim.9115
Hamilton, Lee, Arnold, Lilford, Hemming, Is convalescent plasma futile in COVID-19? A Bayesian re-analysis of the RECOVERY randomized controlled trial, Int J Infect Dis, doi:10.1016/j.ijid.2021.06.034
Herrera, Morano, Celikgil, Characterization of the SARS-CoV-2 S protein: biophysical, biochemical, structural, and antigenic analysis, ACS Omega, doi:10.1021/acsomega.0c03512
Horby, Lim, Emberson, None
Hróbjartsson, Gøtzsche, Gluud, The controlled clinical trial turns 100 years: Fibiger's trial of serum treatment of diphtheria, BMJ, doi:10.1136/bmj.317.7167.1243
Joyner, Carter, Senefeld, Convalescent plasma antibody levels and the risk of death from Covid-19, N Engl J Med, doi:10.1056/NEJMoa2031893
Kraft, Hewlett, Koepsell, None
Kunze, Johnson, Van Helmond, Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors, Nat Commun, doi:10.1038/s41467-021-25113-5
Körper, Weiss, Zickler, Results of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients, J Clin Invest, doi:10.1172/JCI152264
Liu, Lin, Baine, Convalescent plasma treatment of severe COVID-19: a propensity Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients Original Investigation Research jamainternalmedicine.com, JAMA Internal Medicine
Luke, Kilbane, Jackson, Hoffman, Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?, Ann Intern Med, doi:10.7326/0003-4819-145-8-200610170-00139
Maiztegui, Fernandez, De Damilano, Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome, Lancet, doi:10.1016/S0140-6736(79)92335-3
Mcguire, Redden, The use of convalescent human serum in influenza pneumonia-a preliminary report, Am J Public Health, doi:10.2105/AJPH.8.10.741
Petkova, Antman, Troxel, Pooling data from individual clinical trials in the COVID-19 era, JAMA, doi:10.1001/jama.2020.13042?utm_campaign=articlePDF%26utm_medium=articlePDFlink%26utm_source=articlePDF%26utm_content=jamainternmed.2021.6850
Plasma, Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research, Lancet Infect Dis, doi:10.1016/S1473-3099(20)30483-7
Simonovich, Pratx, Scibona, Group. A randomized trial of convalescent plasma in Covid-19 severe pneumonia, N Engl J Med, doi:10.1056/NEJMoa2031304
Thompson, Baumgartner, Pichardo, COVID-19 Outbreak-New York City, MMWR Morb Mortal Wkly Rep, doi:10.15585/mmwr.mm6946a2
Thompson, Henderson, Shah, None
Thompson, Hughes, Ngai, Rapid emergence and epidemiologic characteristics of the SARS-CoV-2 B.1.526 variant-New, MMWR Morb Mortal Wkly Rep, doi:10.15585/mmwr.mm7019e1
Wrapp, Wang, Corbett, Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation, Science, doi:10.1126/science.abb2507
Wu, Zhao, Yu, A new coronavirus associated with human respiratory disease in China, Nature, doi:10.1038/s41586-020-2008-3
Yoon, Bartash, Gendlina, Treatment of severe COVID-19 with convalescent plasma in Bronx, NYC, doi:10.1172/jci.insight.142270
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit